TESARO, Inc. (TSRO) Receives “Neutral” Rating from Janney Montgomery Scott
A number of other research analysts have also recently weighed in on TSRO. Zacks Investment Research upgraded shares of TESARO from a sell rating to a hold rating in a research report on Friday, March 31st. Cowen and Company set a $145.00 price objective on shares of TESARO and gave the company a hold rating in a research report on Saturday, June 10th. Gabelli started coverage on shares of TESARO in a research report on Friday, July 7th. They set a buy rating and a $175.00 price objective on the stock. FBR & Co cut their price objective on shares of TESARO from $202.00 to $200.00 and set a mkt perform rating on the stock in a research report on Wednesday, May 10th. Finally, Robert W. Baird reiterated a neutral rating on shares of TESARO in a research report on Tuesday, June 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of Buy and an average price target of $173.74.
TESARO (TSRO) traded down 4.25% on Friday, hitting $120.81. 1,247,071 shares of the stock were exchanged. TESARO has a 12 month low of $83.26 and a 12 month high of $192.94. The stock’s market cap is $6.51 billion. The company has a 50-day moving average of $146.21 and a 200-day moving average of $151.73.
TESARO (NASDAQ:TSRO) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. The business had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.84 million. TESARO had a negative net margin of 910.35% and a negative return on equity of 96.49%. TESARO’s revenue for the quarter was up 909.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($2.22) EPS. On average, equities analysts predict that TESARO will post ($8.75) EPS for the current year.
In other TESARO news, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now directly owns 5,396 shares in the company, valued at approximately $748,155.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 34.60% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. raised its stake in TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock valued at $524,643,000 after buying an additional 3,335,611 shares during the last quarter. Norges Bank purchased a new stake in TESARO during the fourth quarter valued at approximately $40,158,000. TIAA CREF Investment Management LLC raised its stake in TESARO by 167.9% in the first quarter. TIAA CREF Investment Management LLC now owns 367,519 shares of the biopharmaceutical company’s stock valued at $56,550,000 after buying an additional 230,353 shares during the last quarter. Bank of New York Mellon Corp raised its stake in TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock valued at $103,954,000 after buying an additional 175,273 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in TESARO by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock valued at $448,705,000 after buying an additional 103,759 shares during the last quarter.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.